The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex to present its NASH models at EASL NAFLD Summit 2017

News detail

Return to all news & events

11/08/2017 Physiogenex to present its NASH models at EASL NAFLD Summit 2017

Physiogenex will present at the EASL NAFLD Summit in Rome, Italy, November 9th-11th, 2017.

Dr. François Briand, Director of Research and Business Development, will be presenting an e-poster about the effects of obeticholic acid in various Physiogenex preclinical NASH models, during the e-poster session 3, Nov. the 9th, 08:00pm-08:20pm.

If you wish to further discuss about our NASH models to optimize your preclinical drug development program,

please contact us to set-up an appointment with Dr. François Briand during the EASL NAFLD summit.

We look forward seeing you in Rome, Italy!

About Physiogenex

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.

Please visit our website for more information